Global Acute Myeloid Leukemia (AML) Treatment Market US$ 1.17 Billion 2021

Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children. In 2017, in the United States, an estimated 21,380 people will be diagnosed with AML.

The global acute myeloid leukemia treatment market expected to reach US$ 1.17 billion by 2021, growing at CAGR 15% over the forecast period 2017-2021, owing to introduction of high-priced products and strong pipeline of upcoming drugs. During the forecast period, the marketed drugs, pipeline drugs and others are predicted to contribute 55%, 35%, and 10% market share of the global acute myeloid leukemia drugs market, respectively.

Visit Acute Myeloid Leukemia Treatment Market by Drug Type - Hypomethylating Agents - Vidaza (Azacitidine), Dacogen (Decitabine), Cytarabine-based Chemotherapy Drugs, Others; by Pipeline Analysis (Phase III Drugs) - Chemotherapy Drugs, Vyxeos (Fixed-combination Drugs: Daunorubicin and Cytarabine); Kinase Inhibitors (Midostaurin, Quizartinib) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/global-acute-myeloid-leukemia-treatment-market/

The global acute myeloid leukemia treatment market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global acute myeloid leukemia treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global acute myeloid leukemia treatment market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global acute myeloid leukemia treatment market and profiled in this report include Astellas Pharma, Astex Pharmaceuticals, Bayer, Boehringer Ingelheim, Celgene (Agios–Celgene), Cyclacel Pharmaceuticals, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Onyx Pharma, Otsuka Pharmaceuticals, Pfizer, Roche, Seattle Genetics, Sunesis Pharmaceuticals, and Synta Pharmaceuticals.
https://www.ihealthcareanalyst.com/global-acute-myeloid-leukemia-treatment-market/

1. Drug Type
1.1. Hypomethylating Agents
1.1.1. Vidaza (Azacitidine)
1.1.2. Dacogen (Decitabine)
1.2. Cytarabine-based Chemotherapy Drugs
1.3. Others

2. Pipeline Analysis (Phase III Drugs)
2.1. Chemotherapy Drugs
2.2. Vyxeos (Fixed-combination Drugs: Daunorubicin and Cytarabine)
2.3. Kinase Inhibitors
2.3.1. Midostaurin
2.3.2. Quizartinib

3. Geography
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC
3.5. Rest of the World

4. Company Profiles
4.1. Astellas Pharma
4.2. Astex Pharmaceuticals
4.3. Bayer
4.4. Boehringer Ingelheim
4.5. Celgene (Agios–Celgene)
4.6. Cyclacel Pharmaceuticals
4.7. Daiichi Sankyo
4.8. Jazz Pharmaceuticals
4.9. Novartis
4.10. Onyx Pharma
4.11. Otsuka Pharmaceuticals
4.12. Pfizer
4.13. Roche
4.14. Seattle Genetics
4.15. Sunesis Pharmaceuticals
4.16. Synta Pharmaceuticals

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/acute-myeloid-leukemia-drugs-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com

This release was published on openPR.